Literature DB >> 15192083

Simultaneous alpha2B- and beta2-adrenoceptor activation sensitizes the alpha2B-adrenoceptor for agonist-induced down-regulation.

Aarti N Desai1, Kelly M Standifer, Douglas C Eikenburg.   

Abstract

We recently reported that alpha(2A)-adrenoceptor (AR) desensitization and down-regulation occurs after 24-h treatment with epinephrine (EPI) (0.3 microM) in BE(2)-C cells that express both alpha(2)- and beta(2)-ARs. The same concentration of norepinephrine (NE) has no effect. The effect of EPI is prevented by beta(2)-AR blockade and is associated with an increase in G protein-coupled receptor kinase 3 (GRK3) expression. Because differences in agonist-induced down-regulation of the alpha(2A)-versus alpha(2B)-ARs have been reported, the present study examines the effects of simultaneous activation of alpha(2B)- and beta(2)-ARs on alpha(2B)-AR number and signaling. We studied NG108 cells that naturally express alpha(2B)-ARs, and BN17 cells, NG108 cells transfected to express the human beta(2)-AR. In NG108 cells, alpha(2B)-AR desensitization and down-regulation require treatment with 20 microM EPI or NE; GRK expression was not changed. In BN17 cells expressing beta(2)-ARs, the threshold EPI concentration for alpha(2B)-AR desensitization and down-regulation was reduced to 0.3 microM; 10 microM NE was required for the same effect. Furthermore, 24-h EPI or NE treatments that produced desensitization also resulted in a selective 2-fold up-regulation of GRK3; GRK2 was unchanged. The beta-AR antagonist alprenolol (1 microM) and GRK3 antisense (but not sense) DNA blocked 0.3 microM EPI- and 10 microM NE-induced desensitization and down-regulation of the alpha(2B)-AR as well as GRK3 up-regulation. In conclusion, simultaneous activation of alpha(2B)- and beta(2)-ARs results in a 67-fold decrease in the threshold concentration of EPI required for alpha(2B)-AR down-regulation. This lower threshold for down-regulation is associated with alpha(2B)- and beta(2)-AR dependent up-regulation of GRK3 expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192083     DOI: 10.1124/jpet.104.069674

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Independent regulation of α1 and α2 adrenergic receptor-mediated vasoconstriction in vivo.

Authors:  Mordechai Muszkat; Daniel Kurnik; Gbenga G Sofowora; Alastair J J Wood; C Michael Stein
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

2.  Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation.

Authors:  C Pérez Piñero; A Bruzzone; M G Sarappa; L F Castillo; I A Lüthy
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Crosstalk between β2- and α2-Adrenergic Receptors in the Regulation of B16F10 Melanoma Cell Proliferation.

Authors:  Paola Matarrese; Sonia Maccari; Barbara Ascione; Rosa Vona; Vanessa Vezzi; Tonino Stati; Maria Cristina Grò; Giuseppe Marano; Caterina Ambrosio; Paola Molinari
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

4.  Chronic adrenaline treatment fails to down-regulate the Del301-303-alpha2B-adrenoceptor in neuronal cells.

Authors:  S Salim; A N Desai; M Taneja; D C Eikenburg
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

5.  Cross-talk from β-adrenergic receptors modulates α2A-adrenergic receptor endocytosis in sympathetic neurons via protein kinase A and spinophilin.

Authors:  Christopher Cottingham; Roujian Lu; Kai Jiao; Qin Wang
Journal:  J Biol Chem       Date:  2013-08-21       Impact factor: 5.157

6.  The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment.

Authors:  Tasneem Bawa-Khalfe; Ghazi F Altememi; Chitra D Mandyam; Lindsay A Schwarz; Douglas C Eikenburg; Kelly M Standifer
Journal:  BMC Pharmacol       Date:  2007-12-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.